hope rugo, md, shares the design and outcomes of keynote-355 presented at sabcs 2020

Published 3 years ago • 130 plays • Length 4:54

Download video MP4
Download video MP3

Similar videos

1:42

hope rugo, md, offers key takeaways for physicians regarding keynote-355
3:31

hope rugo, md, examines data from the destiny-breast01 clinical study presented at sabcs 2020
1:26

hope rugo, md, considers chemotherapy recommendations based on findings from keynote-355
4:50

hope rugo, md, provides perspective on the clinical progress of cdk 4/6 inhibitors in breast cancer
2:07

keynote-355: pembrolizumab in triple-negative breast cancer
4:01

keynote-355: outcomes in pts discontinuing chemo before pembro and in pts with immune-mediated aes
2:02

hope rugo, md, considers the incidence of tnbc and what makes this disease so difficult to treat
1:00:31

inspired | beyond the white coat with dr. hope rugo
12:30

immunotherapy treatments finished (keytruda) / triple negative breast cancer
13:44

first chemo treatment for tnbc. keynote 522
7:42

the complexities of battling triple-negative breast cancer
1:30

keynote-355: hrqol unaffected by the addition of pembrolizumab to chemotherapy for tnbc
2:34

esmo 2021 breast cancer highlights: tulip and keynote-355
49:25

optimizing therapy in her2 disease with dr. hope s. rugo
3:12

sara hurvitz, md, shares design and outcomes of the her2climb study in advanced breast cancer
10:14

sabcs updates with hope s. rugo, md
4:49

keynote-355: pembro chemo in triple-negative breast cancer
11:53

new developments in triple-negative breast cancer therapies - medpage today
4:20

keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
1:03

debra patt, md, phd, mba, comments on findings from the keynote-355 trial
3:18

#esmo21 highlights on combination of pembrolizumab plus chemotherapy in mtnbc: the keynote-355 study
12:45

keynote-355: first-line pembrolizumab plus chemotherapy for metastatic triple-negative breast ca...

Clip.africa.com - Privacy-policy